Instrument Inactif

Communiqués Theseus Pharmaceuticals, Inc.

Actions

THRX

US88369M1018

Recherche biotechnologique et médicale

Communiqués

14/02/24	Theseus Pharmaceuticals Announces Closing of Tender Offer	PR
30/01/24	Concentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus Pharmaceuticals	BU
31/12/23	THESEUS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Theseus Pharmaceuticals, Inc. - THRX	BU
22/12/23	Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right	PR
27/11/23	Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC	PR
13/11/23	Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives	PR
07/11/23	Theseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare Conference	PR
10/08/23	Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results	PR
13/07/23	Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST	PR
09/06/23	THESEUS PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
31/05/23	Theseus Pharmaceuticals to Participate in the Jefferies Healthcare Conference	PR
25/05/23	Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST	PR
12/05/23	Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial Results	AQ
11/04/23	Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences	PR
28/03/23	Theseus Pharmaceuticals to Participate in the Cantor Future of Oncology Virtual Symposium	PR
09/03/23	THESEUS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
09/03/23	Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results	PR
07/02/23	Theseus Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference	PR
05/01/23	THESEUS PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
05/01/23	Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program	PR
03/11/22	THESEUS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
26/10/22	Theseus Pharmaceuticals Presents Preclinical Data Characterizing THE-349, its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR Symposium	PR
19/10/22	THESEUS PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
19/10/22	Theseus Pharmaceuticals Appoints Steven Stein, M.D. to Board of Directors	PR
03/10/22	Theseus Pharmaceuticals Nominates THE-349, a Fourth-Generation EGFR Inhibitor Development Candidate in Non-Small Cell Lung Cancer	PR